Yes. Our concern is that the workload for the drug approval process has been increasing as the complexity of the reviews increases and as the A-based funding--as was explained with respect to Ag Canada--is being eroded. They are recommending a cost-recovery program, which they're going to bring forward this fall, which we've supported on the grounds that it's tied to efficiency. But our concern has been that the A-based funding mechanism hasn't kept up with the workload.
On October 18th, 2010. See this statement in context.